The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice

Br J Pharmacol. 2010 Feb;159(4):888-97. doi: 10.1111/j.1476-5381.2009.00571.x. Epub 2010 Jan 8.

Abstract

Background and purpose: Activation of the proteinase-activated receptor-2 (PAR-2) induces scratching behaviour in mice. Here, we have investigated the role of kinin B(1) and B(2) receptors in the pruritogenic response elicited by activators of PAR-2.

Experimental approach: Scratching was induced by an intradermal (i.d.) injection of trypsin or the selective PAR-2 activating peptide SLIGRL-NH(2) at the back of the mouse neck. The animals were observed for 40 min and their scratching response was quantified.

Key results: I.d. injection of trypsin or SLIGRL-NH(2) evoked a scratching behaviour, dependent on PAR-2 activation. Mice genetically deficient in kinin B(1) or B(2) receptors exhibited reduced scratching behaviour after i.d. injection of trypsin or SLIGRL-NH(2). Treatment (i.p.) with the non-peptide B(1) or B(2)receptor antagonists SSR240612 and FR173657, respectively, prevented the scratching behaviour caused by trypsin or SLIGRL-NH(2). Nonetheless, only treatment i.p. with the peptide B(2)receptor antagonist, Hoe 140, but not the B(1)receptor antagonist (DALBK), inhibited the pruritogenic response to trypsin. Hoe 140 was also effective against SLIGRL-NH(2)-induced scratching behaviour when injected by i.d. or intrathecal (i.t.) routes. Also, the response to SLIGRL-NH(2) was inhibited by i.t. (but not by i.d.) treatment with DALBK. Conversely, neither Hoe 140 nor DALBK were able to inhibit SLIGRL-NH(2)-induced scratching behaviour when given intracerebroventricularly (i.c.v.).

Conclusions and implications: The present results demonstrated that kinins acting on both B(1) and B(2) receptors played a crucial role in controlling the pruriceptive signalling triggered by PAR-2 activation in mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipruritics / administration & dosage
  • Behavior, Animal* / drug effects
  • Bradykinin / administration & dosage
  • Bradykinin / analogs & derivatives
  • Bradykinin B1 Receptor Antagonists
  • Bradykinin B2 Receptor Antagonists
  • Dioxoles / administration & dosage
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Injections, Intradermal
  • Injections, Intraperitoneal
  • Injections, Intraventricular
  • Injections, Spinal
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Oligopeptides / administration & dosage
  • Pain Threshold
  • Pruritus / chemically induced
  • Pruritus / genetics
  • Pruritus / metabolism*
  • Pruritus / prevention & control
  • Pruritus / psychology
  • Quinolines / administration & dosage
  • Receptor, Bradykinin B1 / deficiency
  • Receptor, Bradykinin B1 / genetics
  • Receptor, Bradykinin B1 / metabolism*
  • Receptor, Bradykinin B2 / deficiency
  • Receptor, Bradykinin B2 / genetics
  • Receptor, Bradykinin B2 / metabolism*
  • Receptor, PAR-2 / agonists
  • Receptor, PAR-2 / metabolism*
  • Sulfonamides / administration & dosage
  • Trypsin / administration & dosage

Substances

  • 2-((3-(1,3-benzodioxol-5-yl)-3-(((6-methoxy-2-naphthyl)sulfonyl)amino)propanoyl)amino)-3-(4-((2,6-dimethylpiperidinyl)methyl)phenyl)-N-isopropyl-N-methylpropanamide
  • Antipruritics
  • Bradykinin B1 Receptor Antagonists
  • Bradykinin B2 Receptor Antagonists
  • Dioxoles
  • FR 173657
  • Oligopeptides
  • Quinolines
  • Receptor, Bradykinin B1
  • Receptor, Bradykinin B2
  • Receptor, PAR-2
  • Sulfonamides
  • seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide
  • bradykinin, Leu(8)-des-Arg(9)-
  • icatibant
  • Trypsin
  • Bradykinin